After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.
Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma
Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy
Dr Kyriakopoulos on the Investigation of Masofaniten Plus Enzalutamide in mCRPC
Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma
Study Provides a First Look at Oncologists' Views on Ethical Implications of AI in Cancer Care
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma